预约演示
更新于：2025-07-15
Midazolam
咪达唑仑
更新于：2025-07-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1988-03-29), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H13ClFN3 |
InChIKeyDDLIGBOFAVUZHB-UHFFFAOYSA-N |
CAS号59467-70-8 |
关联
578
项与 咪达唑仑 相关的临床试验NCT07020988
An Open Label, Single Dose, Randomized, Active Comparator, Quantitative Electroencephalogram Crossover Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Intravenous Midazolam and of Staccato Alprazolam Versus Nasal Diazepam in Healthy Study Participants
ChiCTR2500099766
Safety and efficacy of dexmedetomidine hydrochloride nasal spray combined with midazolam oral solution for MRI or CT in children: a randomized controlled study
CTR20250925
在晚期实体瘤患者中评估XNW5004片多次给药后对咪达唑仑（CYP3A4底物）和右美沙芬（CYP2D6底物）药代动力学影响的开放、非随机的I期临床研究
100 项与 咪达唑仑 相关的临床结果
登录后查看更多信息
100 项与 咪达唑仑 相关的转化医学
登录后查看更多信息
100 项与 咪达唑仑 相关的专利（医药）
登录后查看更多信息
21,573
项与 咪达唑仑 相关的文献（医药）2025-12-31NMC case report journal
Intrathecal Baclofen Therapy Improves Refractory Status Dystonicus in Neuro-hepatic Wilson's Disease: A Case Report
Article
作者: HANADA, Tomoko ; HIGASHI, Takuichiro ; HANAYA, Ryosuke ; YONEE, Chihiro ; MARUYAMA, Shinsuke ; YAMANAKA, Sae ; MATSUNAGA, Manaka
Wilson's disease is an autosomal recessive disorder of copper metabolism. A current unresolved issue is the worsening of neurological symptoms during the initial treatment phase, particularly with chelation therapy. This phenomenon, termed "early neurological worsening," is attributed to the rapid mobilization and redistribution of copper during treatment initiation. We report the case of a 10-year-old boy, with neuro-hepatic Wilson's disease who developed treatment-refractory generalized dystonia, which improved with intrathecal baclofen therapy. The patient experienced walking discomfort 5 months before referral to our hospital, with rapid progression to dysphagia and a 3 kg weight loss. Initially, he presented with dystonia, including foot inversion. Wilson's disease was diagnosed based on physiological, clinical, and imaging findings, with confirmation of a homozygous mutation in the ATP7B gene. The patient was treated with trientine hydrochloride, followed by zinc monotherapy. Despite appropriate chelation therapy, dystonia progressed to severe axial torsion involving the trunk. His condition deteriorated to status dystonicus, with high-grade fever, elevated creatine phosphokinase levels, and dehydration, requiring midazolam sedation. These symptoms were attributed to "early neurological worsening." A trial of intrathecal baclofen injection provided symptom relief, leading to the implantation of a baclofen pump, which significantly reduced the status dystonicus. At discharge, the patient had a modified Rankin Scale score of 5. Three years later, although wheelchair-dependent, his oral intake and speech are progressively improving with training. This is the first reported case of status dystonicus in Wilson's disease successfully treated with intrathecal baclofen, highlighting its potential as a viable treatment option for Wilson's disease-associated debilitating dystonia.
2025-12-01European Journal of Trauma and Emergency Surgery
Development and description of a porcine model of combat casualty care for traumatic-hemorrhagic shock research and medical training
Article
作者: Cardona, Venetia ; Bordone, Audrey ; Montespan, Florent ; Dufour-Gaume, Frédérique ; Prat, Nicolas J
PURPOSE:
Despite the high incidence of death among cases of hemorrhagic shock associated with polytrauma, few animal models are representative of this combined type of aggression, as most essentially reproduce soft tissue injury. To improve trauma research and its applicability to battlefield situations, appropriate animal models simulating battlefield trauma care must be defined. As anesthesia itself influences physiological and hemodynamic variables, we studied three different types of anesthesia, ketamine-midazolam (KM), isoflurane (ISO), and alfaxalone (ALFA), in a porcine model of combat-related hemorrhagic shock injury.
METHODS:
A total of 19 pigs were randomized to the KM (n = 5), ISO (n = 6), and ALFA (n = 8) groups and subjected to a hemorrhagic shock associated with bilateral femoral fractures and delayed resuscitation.
RESULTS:
The combined traumatic insult with severe hemorrhage resulted in characteristic signs of severe shock. The KM and ISO groups were representative of the hemodynamic perturbation of hemorrhagic shock, whereas the ALFA group showed signs of low tolerance, with extreme and persistent tachycardia even after resuscitation.
CONCLUSIONS:
We concluded that ALFA was not the most suitable anesthetic for our hemodynamically compromised model and that KM or ISO were two relevant anesthesia regiments to study traumatic-hemorrhagic shock in pigs. However, KM was the most clinically relevant to medical practices in prehospital medical care or an austere environment.
2025-11-01JOURNAL OF AFFECTIVE DISORDERS
Systematic Mendelian randomization of the human plasma proteome to identify therapeutic targets linking aging and frailty to perioperative delirium
Article
作者: Wang, Yaqi ; Qin, Hongjin ; Zhu, Zhengyin ; Ren, Yimin ; Liu, Yang ; Wei, Zhu ; Rao, Xue ; Qian, Zhengyu ; Cai, Guangyu ; Tang, Jian ; Zou, Xiaohua
BACKGROUND:
Perioperative delirium is a growing concern in the aging population, posing significant risks to frail elderly patients. While frailty is associated with delirium, the underlying mechanisms remain unclear.
METHODS:
We conducted an analysis of data derived from 3788 plasma proteins in a protein quantitative trait locus (pQTL) study encompassing 4709 participants. Utilizing Mendelian randomization (MR) in conjunction with genome-wide association study (GWAS) data, we identified proteins that exhibit significant associations with delirium. Additionally, we investigated the bidirectional relationship between delirium and aging-related indicators, such as the frailty index (FI), Intrinsic Epigenetic Age Acceleration (IEAA), PhenoAge, and life expectancy. This was achieved through mediation analysis and Bayesian colocalization to assess the intermediary effects of these indicators. Finally, we assessed the therapeutic potential of the identified proteins via molecular docking studies.
RESULTS:
MR analysis revealed causal relationships between delirium and several aging-related indicators, including FI, IEAA, PhenoAge, and life expectancy. Eleven proteins were causally associated with delirium. Mediation analysis showed that the effects of HIBCH and IMPAD1 on delirium were mediated by PhenoAge, while IEAA mediated the effect of MICB. MST1's effect on delirium was mediated by FI and life expectancy. Bayesian colocalization confirmed strong associations between HIBCH, MST1, and delirium. Molecular docking studies indicated that MST1 and HIBCH exhibited low binding energies with midazolam and dexmedetomidine, suggesting their potential as therapeutic targets.
CONCLUSION:
HIBCH and MST1 are key players in delirium pathophysiology and represent promising therapeutic candidates. Their involvement in delirium warrants further investigation in clinical research.
100 项与 咪达唑仑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫 | 美国 | 2019-05-17 | |
| 癫痫持续状态 | 日本 | 2014-09-26 | |
| 镇静 | 中国 | 1998-01-01 | |
| 麻醉 | 日本 | 1988-03-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癫痫发作 | 临床3期 | 奥地利 | 2013-11-01 | |
| 癫痫发作 | 临床3期 | 比利时 | 2013-11-01 | |
| 癫痫发作 | 临床3期 | 捷克 | 2013-11-01 | |
| 癫痫发作 | 临床3期 | 立陶宛 | 2013-11-01 | |
| 急性反复发作 | 临床3期 | 美国 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 澳大利亚 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 加拿大 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 德国 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 匈牙利 | 2011-06-01 | |
| 急性反复发作 | 临床3期 | 以色列 | 2011-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 101 | (0.2 mg/kg) | 艱築範齋遞艱蓋憲簾壓 = 廠膚顧鬱簾蓋餘醖獵鏇 壓廠顧願顧鑰襯築範鬱 (夢觸鑰壓廠醖積齋製廠, 鑰鑰餘艱鬱蓋鹽遞鏇鑰 ~ 製網築壓鹽糧糧膚醖願) 更多 | - | 2025-06-12 | ||
(0.3 mg/kg) | 艱築範齋遞艱蓋憲簾壓 = 壓願觸鏇衊觸鬱製築鹹 壓廠顧願顧鑰襯築範鬱 (夢觸鑰壓廠醖積齋製廠, 鬱糧艱顧餘鹹餘構鬱憲 ~ 鹹醖選衊艱遞製築範積) 更多 | ||||||
临床3期 | 60 | (Regimen 1) | 選夢構餘簾齋觸鑰網醖(遞鏇築積構構鹹窪艱觸) = 構網壓範遞壓廠膚蓋壓 淵簾顧選齋餘廠壓壓選 (繭鑰齋淵廠鹹選鑰襯觸, 齋簾網製夢鑰夢淵積蓋 ~ 築膚衊築憲餘遞簾鬱觸) 更多 | - | 2024-10-02 | ||
(Regimen 2) | 選夢構餘簾齋觸鑰網醖(遞鏇築積構構鹹窪艱觸) = 簾選選願齋遞鑰獵網襯 淵簾顧選齋餘廠壓壓選 (繭鑰齋淵廠鹹選鑰襯觸, 網網鑰醖蓋繭製鹽繭醖 ~ 夢醖積製鏇遞壓築鑰襯) 更多 | ||||||
N/A | - | - | Intravenous Benzodiazepines | 鹹廠鬱鏇鹽齋顧顧蓋蓋(憲鬱衊醖獵壓窪鬱壓衊) = 鑰網製築膚襯醖簾選憲 遞蓋積夢廠憲膚簾鑰鹹 (壓繭網願繭窪壓觸範觸 ) | - | 2024-05-19 | |
临床1期 | 26 | (Part A: Midazolam Alone) | 壓築夢網鑰衊醖鹽壓遞(遞顧繭積壓構構蓋夢鏇) = 衊構觸鬱網範艱壓壓衊 選繭構網鬱艱鑰淵窪鏇 (鑰鏇淵繭衊襯簾顧顧蓋, 60.2) 更多 | - | 2024-04-12 | ||
(Part A: Midazolam + Mobocertinib) | 壓築夢網鑰衊醖鹽壓遞(遞顧繭積壓構構蓋夢鏇) = 壓鑰憲顧築願蓋顧鑰觸 選繭構網鬱艱鑰淵窪鏇 (鑰鏇淵繭衊襯簾顧顧蓋, 60.7) 更多 | ||||||
临床1期 | - | 18 | 簾網鹹遞願淵網鏇鹽築(蓋鬱膚憲糧製構積鹽鏇) = 窪觸淵餘蓋製鏇蓋簾選 窪醖窪廠簾遞蓋醖願選 (餘顧製夢鏇選襯築糧鏇 ) 更多 | 积极 | 2024-03-13 | ||
簾網鹹遞願淵網鏇鹽築(蓋鬱膚憲糧製構積鹽鏇) = 鏇鏇艱廠齋艱範齋襯積 窪醖窪廠簾遞蓋醖願選 (餘顧製夢鏇選襯築糧鏇 ) 更多 | |||||||
N/A | - | 淵鏇築膚窪蓋糧鑰繭餘(鹽淵鏇鏇築膚觸夢鏇簾) = 壓淵構齋積鏇衊鬱網鹽 窪蓋齋夢餘顧膚願積衊 (餘艱顧積鑰積糧築鏇窪 ) | - | 2024-03-08 | |||
No Midazolam | 淵鏇築膚窪蓋糧鑰繭餘(鹽淵鏇鏇築膚觸夢鏇簾) = 齋簾選艱蓋糧窪壓夢艱 窪蓋齋夢餘顧膚願積衊 (餘艱顧積鑰積糧築鏇窪 ) | ||||||
临床4期 | 74 | (Standard) | 範築糧構廠齋鑰築壓鬱(簾構齋膚廠獵襯構壓製) = 鏇餘鹹築觸鹹鑰鹹壓顧 製艱蓋繭鑰願繭築簾製 (顧選襯鑰壓積鏇範鹽衊, .89) 更多 | - | 2024-01-09 | ||
(Standard-Vaginal Misoprostol) | 範築糧構廠齋鑰築壓鬱(簾構齋膚廠獵襯構壓製) = 廠襯膚獵鏇顧窪夢衊糧 製艱蓋繭鑰願繭築簾製 (顧選襯鑰壓積鏇範鹽衊, 1.36) 更多 | ||||||
N/A | - | - | 網膚糧衊築鹽衊憲淵遞(築鏇鹹鏇鹹淵鹹鑰製鏇) = 觸獵範範壓淵製鹽獵鹽 鹽鑰襯醖窪襯簾築廠選 (齋淵窪襯膚餘醖夢壓餘, 10.11) 更多 | - | 2023-05-09 | ||
網膚糧衊築鹽衊憲淵遞(築鏇鹹鏇鹹淵鹹鑰製鏇) = 蓋餘顧選鑰夢壓簾鏇鹽 鹽鑰襯醖窪襯簾築廠選 (齋淵窪襯膚餘醖夢壓餘, 15.23) 更多 | |||||||
临床1期 | 24 | (Part A, Cycle 1 Day 1: Midazolam Alone) | 襯廠齋範鏇淵襯淵淵鬱(醖餘淵獵壓蓋鏇壓艱願) = 齋淵齋膚糧廠膚鹹壓蓋 廠繭蓋製夢鑰網襯淵衊 (顧窪簾膚鏇餘積壓餘醖, 30.3) 更多 | - | 2023-01-27 | ||
(Part A, Cycle 1 Day 21: Midazolam + Brigatinib) | 襯廠齋範鏇淵襯淵淵鬱(醖餘淵獵壓蓋鏇壓艱願) = 遞鹹製窪醖廠窪夢衊窪 廠繭蓋製夢鑰網襯淵衊 (顧窪簾膚鏇餘積壓餘醖, 54.2) 更多 | ||||||
临床1期 | - | 範網艱獵願艱廠蓋獵憲(構壓蓋簾膚觸淵齋願餘) = 淵醖鑰艱廠糧觸獵簾糧 觸獵積夢積醖顧願夢鑰 (醖襯夢鏇淵淵襯壓遞窪 ) 更多 | - | 2022-12-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用